Equity Profile

CRSP

CRISPR Therapeutics AG

Health CareBiotechnology$5.0B

Aug10Mon

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

CRISPR Therapeutics AG is a biotechnology company focused on developing transformative gene-based medicines using CRISPR technology. As part of the health care sector, it aims to address serious diseases by editing genes, which could lead to significant advancements in treatment options.

Key Metrics to Watch

Clinical Trial Progress

Updates on ongoing clinical trials are crucial as they can indicate the potential for future revenue and product launches.

N/A

Research and Development Expenses

High R&D spending is typical for biotech firms, and investors will look for efficiency in spending relative to progress.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

CRSP Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

-4.69%

Avg Stock Reaction

-0.54%

Last Quarter Recap

In Q1-2026, CRISPR reported an EPS of -$1.28, missing estimates by 12.38%. The stock reacted positively, increasing by 3.78% the following day.

Management Promises & Guidance

Continue advancing clinical trials for lead programs.
Focus on strategic partnerships to enhance research capabilities.
Commit to managing R&D expenses effectively.

Expectations

Wall Street Expectations

Overall expectations for CRISPR's upcoming earnings are cautious, given the recent trend of EPS misses. Investors will be looking for any signs of progress in clinical trials and partnerships.

Bull Case

If CRISPR can demonstrate significant advancements in its clinical trials or secure new partnerships, it could lead to a positive reassessment of its growth potential.

Bear Case

Conversely, if the company fails to provide clear updates on its trials or partnerships, it may reinforce concerns about its long-term viability and lead to further stock declines.

Expectations

Two Questions That Matter

The print will turn on these two things.

What progress has been made in clinical trials for key therapies?

Updates on clinical trials are critical as they can significantly impact the company's future revenue potential and investor confidence.

Are there any new partnerships or collaborations announced?

New partnerships can enhance CRISPR's research capabilities and financial outlook, making this a key area of interest for investors.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for CRISPR to secure new partnerships that could significantly enhance its research capabilities.

Supporting Evidence

Recent trends in biotech partnerships suggest increased collaboration opportunities.

The options market is pricing in a larger move than historical averages, indicating potential for surprise.

The company's recent focus on efficiency in R&D spending could yield better-than-expected results.

Key Risk

If CRISPR announces a significant new partnership, it could shift market sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the potential for growth against the backdrop of recent misses and the need for clear advancements.

Bull Confirmed If

Demonstrating significant progress in clinical trials or announcing new partnerships would confirm the bull case.

Bear Confirmed If

Failure to provide updates on clinical trials or partnerships would reinforce the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±26.4%

Historical Avg

±3.5%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±26.4% while CRSP has averaged ±3.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

61.0%

Calls (499K)P/C Ratio: 0.53Puts (93K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If CRISPR beats expectations, history suggests the stock could rise by about 3.6%, confirming a positive outlook for growth.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further clarity from management.

Miss

A miss could lead to a decline in stock price, with history suggesting an average drop of around 0.7%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the progress of clinical trials for lead therapies.
2Any announcements regarding new partnerships or collaborations.
3Management's commentary on R&D spending and efficiency.
4Insights into market conditions affecting the biotechnology sector.
5Future guidance or outlook for the next quarter.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Tempus AI, Inc.

Company Snapshot

Key Metrics to Watch

Clinical Trial Progress

Updates on ongoing clinical trials are crucial as they can indicate the potential for future revenue and product launches.

N/A

Research and Development Expenses

High R&D spending is typical for biotech firms, and investors will look for efficiency in spending relative to progress.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

CRSP Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

-4.69%

Avg Stock Reaction

-0.54%

Last Quarter Recap

In Q1-2026, CRISPR reported an EPS of -$1.28, missing estimates by 12.38%. The stock reacted positively, increasing by 3.78% the following day.

Management Promises & Guidance

Continue advancing clinical trials for lead programs.
Focus on strategic partnerships to enhance research capabilities.
Commit to managing R&D expenses effectively.

Expectations

Wall Street Expectations

Overall expectations for CRISPR's upcoming earnings are cautious, given the recent trend of EPS misses. Investors will be looking for any signs of progress in clinical trials and partnerships.

Bull Case

If CRISPR can demonstrate significant advancements in its clinical trials or secure new partnerships, it could lead to a positive reassessment of its growth potential.

Bear Case

Conversely, if the company fails to provide clear updates on its trials or partnerships, it may reinforce concerns about its long-term viability and lead to further stock declines.

Expectations

Two Questions That Matter

The print will turn on these two things.

What progress has been made in clinical trials for key therapies?

Updates on clinical trials are critical as they can significantly impact the company's future revenue potential and investor confidence.

Are there any new partnerships or collaborations announced?

New partnerships can enhance CRISPR's research capabilities and financial outlook, making this a key area of interest for investors.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for CRISPR to secure new partnerships that could significantly enhance its research capabilities.

Supporting Evidence

Recent trends in biotech partnerships suggest increased collaboration opportunities.

The options market is pricing in a larger move than historical averages, indicating potential for surprise.

The company's recent focus on efficiency in R&D spending could yield better-than-expected results.

Key Risk

If CRISPR announces a significant new partnership, it could shift market sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the potential for growth against the backdrop of recent misses and the need for clear advancements.

Bull Confirmed If

Demonstrating significant progress in clinical trials or announcing new partnerships would confirm the bull case.

Bear Confirmed If

Failure to provide updates on clinical trials or partnerships would reinforce the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±26.4%

Historical Avg

±3.5%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±26.4% while CRSP has averaged ±3.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

61.0%

Calls (499K)P/C Ratio: 0.53Puts (93K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If CRISPR beats expectations, history suggests the stock could rise by about 3.6%, confirming a positive outlook for growth.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further clarity from management.

Miss

A miss could lead to a decline in stock price, with history suggesting an average drop of around 0.7%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the progress of clinical trials for lead therapies.
2Any announcements regarding new partnerships or collaborations.
3Management's commentary on R&D spending and efficiency.
4Insights into market conditions affecting the biotechnology sector.
5Future guidance or outlook for the next quarter.